ScandiDos initiates an 8 MSEK cost-cutting program while pushing the launch of its Delta4 SRS Pro radiation therapy quality assurance system to the second half of 2027 to refine product design.
The company delays the Delta4 SRS Pro launch from late 2026 to the second half of 2027 after identifying technical adjustments needed, pushing expected revenue from a key product about a year into the future. The restructuring cuts the annual cost base by roughly 8 MSEK and targets improved profitability, which partly offsets the delay, but a one-year slip of the flagship launch is typically the dominant driver for a small-cap medtech stock.
During continued development work the company identified a need for technical adjustments and opportunities to improve the product's performance and manufacturability, so it decided on a further development of the product design. The launch is now expected in the second half of 2027 instead of late 2026.
The annual cost base is estimated to decrease by approximately 8 MSEK compared with the current organization, as part of a change effort launched after Olof Stranding became interim CEO in September 2026.
ScandiDos is implementing a restructuring plan to reduce its annual cost base by approximately 8 MSEK, aiming to improve profitability. Simultaneously, the company has postponed the launch of its flagship Delta4 SRS Pro system from late 2026 to the second half of 2027 to accommodate necessary technical design adjustments and enhance manufacturing efficiency.
The company identified a need for technical adjustments and opportunities to improve the product's performance and manufacturability, necessitating a redesign to ensure robust and cost-effective production.
The restructuring is expected to reduce the annual cost base by approximately 8 MSEK compared to the current organization.